formation of specific carcinogen metabolites. This enzymatic The cytochrome P450 family of enzymes is responsible for biotransformation process is necessary to convert lipophilic many of the initial metabolic conversions of procarcinogenic carcinogens to hydrophilic forms that are more readily excreted. compounds in tobacco smoke to reactive metabolites. HowHowever, during metabolic biotransformation, highly carcinoever, other enzyme-based systems such as myeloperoxidase genic metabolites can be formed which are capable of deleteri-(MPO) may also be involved in this metabolic process.
ous effects on genomic integrity.
MPO is a phase I metabolic enzyme that has a polymorphic
MPO has been shown to convert metabolites of the tobacco smoke procarcinogen benzo[a]pyrene (B[a]P) to the highly region upstream of the gene that appears to reduce tranreactive and carcinogenic (ϩ)-anti-diol epoxide (benzo[a] scriptional activity. The polymorphic G→A nucleotide base pyrene diol epoxide, BPDE) (4, 9) . BPDE is carcinogenic and shift negates the binding region for the general transcription mutagenic since it is capable of forming DNA adducts as well factor SP1. Thus, individuals with the variant allele may as causing sister chromatid exchanges. In the presence of be provided with a protective effect due to decreased 
neutrophils, activation of the B[a]P intermediate B[a]P-7,8-metabolic conversion of carcinogenic compounds in tobacco
diol to the carcinogenic BPDE occurs via an MPO-dependent smoke. This study has investigated the hypothesis that system (4 (17) were the first to report many of the initial metabolic conversions of procarcinogenic an association between the variant allele of MPO and lung compounds in tobacco smoke to reactive metabolites. However, cancer risk (OR ϭ 0.30, 95% CI 0.10-0.93, P ϭ 0.04, n ϭ 182 cases). The purpose of this study was to confirm this other enzyme-based systems can also be involved, including previous report and further examine the association between lipoxygenases, cyclooxygenases, epoxide hydrolase, dihydrogenetic polymorphisms of the MPO gene and lung cancer risk diol dehydrogenase, UDP-glucuronosyl transferase and myeloby selected smoking characteristics. peroxidase (MPO) (1, 2) . MPO is a phase I metabolic enzyme found in monocytes/macrophages and primary granules of The numbers are given with the percentages in parentheses. by highly trained staff personnel. The interview elicited information regarding sociodemographics and smoking history. At the conclusion of the interview, a 30 ml peripheral blood sample was drawn into coded heparinized tubes for immediate DNA isolation and subsequent molecular analysis. 
Materials and methods

Study population
8%). The normal theoretical test for the
Smoking status and pack-years were defined in a previous report (19) . Briefly, equality of proportions also demonstrated that the wild-type an ever smoker is defined as an individual who has smoked at least 100 genotype frequencies between the cases and controls were cigarettes in his or her lifetime. A former smoker is defined as an individual significantly different (P ϭ 0.02).
who had smoked cigarettes in the past but stopped at least 1 year prior to diagnosis. For the controls, a former smoker is defined as an individual who
The risk estimates for the MPO variant allele are displayed had stopped smoking 1 year before entering the study. All statistical analyses in Table III . The overall reduction in estimated risk was 48% were performed using STATA statistical software (20). Pearson's χ 2 was used (OR ϭ 0.52, 95% CI 0.30-0.90, P ϭ 0.02). When stratified to test the differences in the distributions between cases and controls. Hardyby gender, we observed a significant reduced estimate of risk Weinberg equilibrium was tested by a goodness-of-fit χ 2 test to compare the observed frequencies with the expected frequencies among the cases and only in men (OR ϭ 0.28, 95% CI 0.12-0.61, P Ͻ 0.05) while controls. All odds ratios were calculated as estimates of the relative risk. The there was no significant association in women (OR ϭ 1.02, crude odds ratios were calculated by the method of Woolf (21) . The adjusted 95% CI 0.44-2.34, P ϭ 0.97). When stratified by the median odds ratios were calculated by logistic regression to control for age, gender age (61 years), younger individuals (Ͻ61 years) were observed and smoking status where appropriate.
to have a significantly reduced estimate of risk (OR ϭ 0.28, 95% CI 0.11-0.69, P Ͻ 0.05) compared with older individuals Results (ജ61 years) (OR ϭ 0.78, 95% CI 0.37-1.64, P ϭ 0.52). An interesting trend was observed when the data were analyzed Table I displays the selected characteristics of our Caucasian population of 93 cases and 121 controls. There were no by smoking status. There was a significant protective effect (OR ϭ 0.24, 95% CI 0.10-0.58, P Ͻ 0.05) for current smokers statistically significant differences between the cases and controls in age, gender, smoking status or any of the smoking with the variant allele but not for former smokers nor those who had never smoked. Significant results were also observed variables, indicating successful matching.
Table II displays the MPO genotype distributions for the when we stratified current smokers by the median age. In younger current smokers there was an 89% reduction in risk cases and controls. A statistically significant difference was (OR ϭ 0.11, 95% CI 0.03-0.40, P Ͻ 0.05) of lung cancer, variant allele may be associated with weaker transcriptional while the protective effect was less evident in older current activity, less enzyme would be available for activation of smokers (OR ϭ 0.65, 95% CI 0.18-2.36, P ϭ 0.44). A B[a]P-7,8-diol. Thus, the variant allele of MPO may be significant 62% reduction in risk (OR ϭ 0.38, 95% CI 0.17-associated with reduced metabolic activity resulting in an 0.86, P ϭ 0.02) was observed in individuals who smoked Ͼ30 overall decrease in lung cancer risk. Our data support this cigarettes/day, compared with individuals who smoked Ͻ30 hypothesis, however, the protective effects were evident only cigarettes/day (OR ϭ 0.69, 95% CI 0.30-1.57, P ϭ 0.38).
in men, younger individuals and current smokers. Similar results regarding tobacco smoke exposure were When the data were stratified by gender we observed a observed when the data were stratified on the median years significant 72% protective effect in men but not women. A smoked. Individuals above the median were at a 64% reduced recent report demonstrated that the wild-type genotype was risk (OR ϭ 0.36, 95% CI 0.17-0.77, P Ͻ 0.05), while in associated with an increased incidence of Alzheimer's disease individuals below the median there was a near null odds ratio in females but a decreased incidence in males (23). These (OR ϭ 0.92, 95% CI 0.39-2.17, P ϭ 0.85).
results suggest a gender-specific effect of the MPO variants. Additionally, Zang and Wynder (24) concluded that gender Discussion differences in overall lung cancer risk cannot be completely explained by baseline exposure, smoking history, body size or The genetic polymorphisms and enzyme activity of MPO have occupational exposure. However, variations in physiological previously been implicated in numerous diseases and biological mechanisms such as the metabolic activation of carcinogens processes (12-16,22,23), including carcinogenesis (4, 9, 17) .
could account for gender differences in overall lung cancer Reynolds et al. (23) reported that individuals with the wildrisk. In support of this theory, Ryberg et al. (25) reported that type genotype (G/G) are at a greater risk for two types of DNA adduct levels were higher in females than in male lung acute promyelocytic leukemias, suggesting that higher levels cancer patients and concluded that women may be at a greater of MPO are associated with an increased risk for these risk of tobacco-induced lung cancer. Previous studies utilizing leukemias. The wild-type genotype was over-represented in animal models have also shown gender differences in the cases with acute promyelocytic leukemias M3 and M4 (80%) bioactivation of specific compounds by P450 metabolic as compared with the general population (60%). Additionally, enzymes (26) (27) (28) . the wild-type genotype was over-represented in patients with
We observed that a 76% protective effect was evident only early onset MS in females (14), suggesting that higher levels for current smokers, but not in former smokers and those who of MPO in macrophages accelerate neural damage. The wildhad never smoked. Since MPO is involved in the metabolism type genotype was observed in 74% of females with MS, of specific tobacco smoke intermediates, current smokers with while only 61% of the general population carried the wildthe variant allele should benefit most from reduced carcinogen type genotype. Lastly, the variant allele was observed to activation. Specifically, the metabolic conversion of specific decrease lung cancer risk in Caucasians by 70% (17) , with procarcinogenic compounds found in tobacco smoke may only case and control A allele frequencies of 0.18 and 0.23, occur when there is a biologically available dose. Therefore, the respectively.
MPO-dependent pathway that produces reactive intermediates During the MPO-dependent biotransformation process, MPO from the tobacco smoke carcinogen B[a]P would not be converts the tobacco smoke intermediate B[a]P-7,8-diol to the highly reactive and carcinogenic product BPDE (4). Since the initiated unless there is a bioavailable dose. Carcinogenic
